首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin
【24h】

In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin

机译:原位粘膜 - 热敏性脂质体凝胶作为鼻延长递送的新型鼻腔

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Graphical abstract Display Omitted Abstract Previous studies proved the effectiveness of an intravenous PEGylated liposomal formulation of opiorphin (1mg/mL) in protecting the drug from enzymatic degradation, and improving intensity and duration of its painkilling effect. Therefore, considering the advantages of nasal administration, the aim of this work was the development of a liposomal mucoadhesive thermo-sensitive in situ gel for the extended nasal delivery of opiorphin. With this purpose, the potential of a series of combinations of different polymers (i.e. chitosan, hydroxypropylmethylcellulose, Poloxamer, Carbopol) in forming solutions able to rapidly gel at the nasal cavity temperature (34 °C) has been investigated. The best formulations were further characterized for gel strength and mucoadhesion properties. The selected formulation, composed by Poloxamer 407 (26.5%) and Carbopol 934P (1%), showed short gelation time at 34 °C (10s) and suitable mucoadhesion duration (5.5h) and strength (27g/cm 2 ). Due to the low volume administrable via the nasal route, a concentrated liposomal formulation of the peptide (16.5mg/mL) was developed and loaded in the selected in situ gel formulation. Ex-vivo permeation studies, by excised nasal porcine mucosa, showed that the liposomal hydrogel formulation enabled a sustained and controlled delivery of opiorphin over more than 5h, and highlighted the role of the liposomal carrier in enhancing up to 6 times permeability coefficient and permeation rate of the peptide through the lipophilic nasal mucosa compared to a free peptide-loaded gel.
机译:图形摘要显示省略摘要摘要先前的研究证明了静脉内聚乙二醇化脂质体制剂的有效性(1mg / ml)保护药物免受酶促降解的影响,提高其止痛作用的强度和持续时间。因此,考虑到鼻腔给药的优点,这项工作的目的是在原位凝胶的延长鼻腔递送的原位凝胶中发育脂质体粘膜热敏的发展。为此目的,已经研究了在能够在鼻腔温度(34℃)的溶液中形成溶液的形成溶液中的一系列不同聚合物(即壳聚糖,羟丙基甲基纤维素,泊洛沙姆,Carbopol)的潜力。最佳制剂进一步表征凝胶强度和粘膜粘附性。由泊洛沙姆407(26.5%)和Carbopol 934p(1%)组成的选定的制剂在34℃(10s)和合适的粘膜粘附持续时间(5.5h)和强度(27g / cm 2)中显示出短的凝胶化时间。由于通过鼻途径可管理的低体积,肽(16.5mg / ml)的浓缩脂质体制物被开发并在原位凝胶制剂中选择并装载。通过切除的鼻猪粘膜的前体内渗透研究表明,脂质体水凝胶制剂使Ophiorphin的持续和受控递送超过5h,并强调了脂质体载体的作用在增强渗透率的渗透系数和渗透率上的作用与游离肽加载的凝胶相比,通过亲脂性鼻粘膜的肽。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号